This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.

Accept

  1. Galileo Research »
  2. Opportunità per Investitori »
  3. Grants

Grants

KEBIC PROJECT

 

REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO FESR 2007-2013 BANDO UNICO R&S - LINEA A

 

  • TITLE: Design of a knowledge database for biosimulation and increase in predictivity and translational productivity of preclinical data in the brain ischemy field.

 

The main goal of the project KEBIC is to create a knowledge database which collects and elaborates the results of a number of biological analysis performed on a brain ischemia animal model, integrating data and extrapolating the significance in their correlations. This integrated data system should allow the determination of the existence of such analytical parameters which could indicate the predictivity and the translation of the preclinical model into the human pathology.

 

TALCO PROJECT

 

REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO FESR 2007-2013 BANDO NEGOZIALE ATTIVITA’ 1.1 - LINEA DI INTERVENTO 1.1.C.

 

  • TITLE: Cytotoxic cell line based Orphan Drug (TALL-104) against ovarian cancer

 

    The goal of the project TALCO is to characterize the TALL-104 cell line from a molecular biological point of view to clarify the mechanisms of their cytotoxic activity and their ability to recognize cancer from normal cells , including their capability to reach the tumor site; in order to determine TALL-104 cell line efficacy in a specific pathology like ovarian cancer, through both in vitro or in vivo on animal model studies. Moreover, to confirm the efficacy and safety in a clinical trial with 40 patients affected by such pathology. The achievement of these goals should result in the availability of a new advanced and innovative therapy, extremely valuable in comparison to current existing therapies in this field, including the autologous cell therapies. In fact, TALL-104 could be the first heterologous cell therapy to be developed across the world.

     

    ACTILA PROJECT

     

    REGIONE TOSCANA / FINANZIAMENTI REGIONALI PER RICERCA E SVILUPPO POR CREO FESR 2007-2013 BANDO UNICO R&S ANNO 2012 – Linea B

     

    • TITLE: New multifunctional technology platform for immunotherapy in cancer: synergy among adoptive allogeneic cell therapy, monoclonal antibodies and immunostimulating molecules

     

    The goal of the project is to tackle on tumoral pathologies potentiating an already native effective technology platform based on citotoxic T-linphocites (TALL-104). Several strategies can be adopted to modify the T-cells to empower futher modes of action; the T-lymphocites can be modified either expressing antibodies capable to selectively link to the tumour or in order to produce a more citotoxic mutant IL-2. Applyng such multifuntional strategies will definetely reduce the escape of tumoral cells.